In the normal fetus, a switch from production of hemoglobin F (alpha 2 gamma 2) to hemoglobin A (alpha 2 beta 2) occurs at 28 to 34 weeks of gestation. In the fetus with beta-hemoglobinopathy or beta-thalassemia, this switch proceeds despite the morbidity that results when production of beta-globin is abnormal or reduced. Since insulin has recently been shown to induce renewed expression of some inactive genes, we studied globin biosynthesis during the natural evolution of the fetal globin switch under conditions of hyperinsulinemia, which occurs in infants of diabetic mothers. Such infants develop in a hyperglycemic environment, which produces reactive hyperinsulinemia. The normal increase in beta-globin production from pre-switch levels did not occur in 9 of 10 such infants at term, as compared with 11 normal infants, in whom the switch occurred by 36 to 39 weeks of gestation (P less than 0.0001). The delay in the switch from gamma-globin to beta-globin in this unique clinical setting may allow identification of physiologic factors that can modulate developmental gene suppression.
This article has been cited by other articles:
Oneal, P. A., Gantt, N. M., Schwartz, J. D., Bhanu, N. V., Lee, Y. T., Moroney, J. W., Reed, C. H., Schechter, A. N., Luban, N. L. C., Miller, J. L.
(2006). Fetal hemoglobin silencing in humans. Blood
108: 2081-2086
[Abstract][Full Text]
Weinberg, R. S., Ji, X., Sutton, M., Perrine, S., Galperin, Y., Li, Q., Liebhaber, S. A., Stamatoyannopoulos, G., Atweh, G. F.
(2005). Butyrate increases the efficiency of translation of {gamma}-globin mRNA. Blood
105: 1807-1809
[Abstract][Full Text]
Dempsey, N. J., Ojalvo, L. S., Wu, D. W., Little, J. A.
(2003). Induction of an embryonic globin gene promoter by short-chain fatty acids. Blood
102: 4214-4222
[Abstract][Full Text]
Atweh, G. F., DeSimone, J., Saunthararajah, Y., Fathallah, H., Weinberg, R. S., Nagel, R. L., Fabry, M. E., Adams, R. J.
(2003). Hemoglobinopathies. ASH Education Book
2003: 14-39
[Abstract][Full Text]
Cowett, R. M.
(2002). The Infant of the Diabetic Mother. NeoReviews
3: e173-189
[Full Text]
He, Z., Russell, J. E.
(2002). A human embryonic hemoglobin inhibits Hb S polymerization in vitro and restores a normal phenotype to mouse models of sickle cell disease. Proc. Natl. Acad. Sci. USA
99: 10635-10640
[Abstract][Full Text]
Boosalis, M. S., Bandyopadhyay, R., Bresnick, E. H., Pace, B. S., Van DeMark, K., Zhang, B., Faller, D. V., Perrine, S. P.
(2001). Short-chain fatty acid derivatives stimulate cell proliferation and induce STAT-5 activation. Blood
97: 3259-3267
[Abstract][Full Text]
Reich, S., Buhrer, C., Henze, G., Ohlendorf, D., Mesche, M., Sinha, P., Kage, A., Muller, C., Vetter, B., Kulozik, A. E.
(2000). Oral isobutyramide reduces transfusion requirements in some patients with homozygous beta -thalassemia. Blood
96: 3357-3363
[Abstract][Full Text]
Smith, R. D., Li, J., Noguchi, C. T., Schechter, A. N.
(2000). Quantitative PCR analysis of HbF inducers in primary human adult erythroid cells. Blood
95: 863-869
[Abstract][Full Text]
Bunn, H. F.
(1999). Induction of Fetal Hemoglobin in Sickle Cell Disease. Blood
93: 1787-1789
[Full Text]
Atweh, G. F., Sutton, M., Nassif, I., Boosalis, V., Dover, G. J., Wallenstein, S., Wright, E., McMahon, L., Stamatoyannopoulos, G., Faller, D. V., Perrine, S. P.
(1999). Sustained Induction of Fetal Hemoglobin by Pulse Butyrate Therapy in Sickle Cell Disease. Blood
93: 1790-1797
[Abstract][Full Text]
Ikuta, T., Kan, Y. W., Swerdlow, P. S., Faller, D. V., Perrine, S. P.
(1998). Alterations in Protein-DNA Interactions in the gamma -Globin Gene Promoter in Response to Butyrate Therapy. Blood
92: 2924-2933
[Abstract][Full Text]
Peters, A., Rohloff, D., Kohlmann, T., Renner, F., Jantschek, G., Kerner, W., Lorenz Fehm, H.
(1998). Fetal Hemoglobin in Starvation Ketosis of Young Women. Blood
91: 691-694
[Abstract][Full Text]
Bunn, H. F.
(1997). Pathogenesis and Treatment of Sickle Cell Disease. NEJM
337: 762-769
[Full Text]
Sher, G. D., Ginder, G. D., Little, J., Yang, S., Dover, G. J., Olivieri, N. F.
(1995). Extended Therapy with Intravenous Arginine Butyrate in Patients with {beta}-Hemoglobinopathies. NEJM
332: 1606-1610
[Abstract][Full Text]
Galanello, R., Cao, A., Olivieri, N.
(1994). Induction of Fetal Hemoglobin in the Presence of Increased 3-Hydroxybutyric Acid Associated with {beta}-Ketothiolase Deficiency. NEJM
331: 746-747
[Full Text]
Perrine, S. P., Ginder, G. D., Faller, D. V., Dover, G. H., Ikuta, T., Witkowska, H. E., Cai, S.-p., Vichinsky, E. P., Olivieri, N. F.
(1993). A Short-Term Trial of Butyrate to Stimulate Fetal-Globin-Gene Expression in the {beta}-Globin Disorders. NEJM
328: 81-86
[Abstract][Full Text]
Bunn, H. F.
(1993). Reversing Ontogeny. NEJM
328: 129-131
[Full Text]
Previous
